AB0 blood group and ovarian cancer survival

Vincenzo Dario Mandato, Federica Torricelli, Valentina Mastrofilippo, Gino Ciarlini, Debora Pirillo, Gianluca Annunziata, Bruno Casali, Martino Abrate, Giovanni Battista La Sala, Lorenzo Aguzzoli

Research output: Contribution to journalArticle

Abstract

Background: Epithelial ovarian cancer is the most lethal gynecological malignancy because is usually diagnosed at advanced stage. New prognostic factors have been investigated but these biomarkers do not have a strong direct relationship with survival. Several studies investigated the association between AB0 blood group with ovarian cancer but with conflicting results. We investigated the association between AB0 blood group and epithelial ovarian cancer patients consecutively surgically treated at our department from 2004 to 2015. Methods: Clinical charts of ovarian cancer patients treated and followed from 2004 to 2015 were checked for inclusion and exclusion criteria. Clinical and pathological data were recorded in an electronic separate, anonymous, password-protected database. All relevant data were extrapolated and used for final analysis. Results: A population of 265 ovarian cancer patients was analyzed in this study. 121 (45.6%) patients presented blood type 0, 112 (42.3%) had blood type A, 23 (8.7%) B and 9 (3.4%) AB. A significantly lower percentage of death (8.7%) in patients with blood type B in comparison with patients presenting different genotypes (group 0: 34.7%, group A: 32.1%, group AB: 22.2%) was found. In invasive serous ovarian cancer patients the analysis showed a 5 fold significant reduction of the risk of death in patients with B genotype. However, postoperative residual tumor resulted the most important prognostic factor for overall survival. Conclusions: AB0 blood group might be a preoperative prognostic factor in epithelial ovarian cancer patients. According to the literature, postoperative residual disease remain the most important prognostic factor also in our study.

Original languageEnglish
Pages (from-to)1949-1957
Number of pages9
JournalJournal of Cancer
Volume10
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Blood Group Antigens
Ovarian Neoplasms
Survival
Genotype
Residual Neoplasm
Risk Reduction Behavior
Biomarkers
Databases

Keywords

  • AB0 blood group
  • Neoadjuvant therapy
  • Ovarian cancer
  • Prognostic factor
  • Residual disease
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Mandato, V. D., Torricelli, F., Mastrofilippo, V., Ciarlini, G., Pirillo, D., Annunziata, G., ... Aguzzoli, L. (2019). AB0 blood group and ovarian cancer survival. Journal of Cancer, 10(9), 1949-1957. https://doi.org/10.7150/jca.29272

AB0 blood group and ovarian cancer survival. / Mandato, Vincenzo Dario; Torricelli, Federica; Mastrofilippo, Valentina; Ciarlini, Gino; Pirillo, Debora; Annunziata, Gianluca; Casali, Bruno; Abrate, Martino; La Sala, Giovanni Battista; Aguzzoli, Lorenzo.

In: Journal of Cancer, Vol. 10, No. 9, 01.01.2019, p. 1949-1957.

Research output: Contribution to journalArticle

Mandato, VD, Torricelli, F, Mastrofilippo, V, Ciarlini, G, Pirillo, D, Annunziata, G, Casali, B, Abrate, M, La Sala, GB & Aguzzoli, L 2019, 'AB0 blood group and ovarian cancer survival', Journal of Cancer, vol. 10, no. 9, pp. 1949-1957. https://doi.org/10.7150/jca.29272
Mandato VD, Torricelli F, Mastrofilippo V, Ciarlini G, Pirillo D, Annunziata G et al. AB0 blood group and ovarian cancer survival. Journal of Cancer. 2019 Jan 1;10(9):1949-1957. https://doi.org/10.7150/jca.29272
Mandato, Vincenzo Dario ; Torricelli, Federica ; Mastrofilippo, Valentina ; Ciarlini, Gino ; Pirillo, Debora ; Annunziata, Gianluca ; Casali, Bruno ; Abrate, Martino ; La Sala, Giovanni Battista ; Aguzzoli, Lorenzo. / AB0 blood group and ovarian cancer survival. In: Journal of Cancer. 2019 ; Vol. 10, No. 9. pp. 1949-1957.
@article{d1f38ad20a0d4b2f9f4914285dd09fc8,
title = "AB0 blood group and ovarian cancer survival",
abstract = "Background: Epithelial ovarian cancer is the most lethal gynecological malignancy because is usually diagnosed at advanced stage. New prognostic factors have been investigated but these biomarkers do not have a strong direct relationship with survival. Several studies investigated the association between AB0 blood group with ovarian cancer but with conflicting results. We investigated the association between AB0 blood group and epithelial ovarian cancer patients consecutively surgically treated at our department from 2004 to 2015. Methods: Clinical charts of ovarian cancer patients treated and followed from 2004 to 2015 were checked for inclusion and exclusion criteria. Clinical and pathological data were recorded in an electronic separate, anonymous, password-protected database. All relevant data were extrapolated and used for final analysis. Results: A population of 265 ovarian cancer patients was analyzed in this study. 121 (45.6{\%}) patients presented blood type 0, 112 (42.3{\%}) had blood type A, 23 (8.7{\%}) B and 9 (3.4{\%}) AB. A significantly lower percentage of death (8.7{\%}) in patients with blood type B in comparison with patients presenting different genotypes (group 0: 34.7{\%}, group A: 32.1{\%}, group AB: 22.2{\%}) was found. In invasive serous ovarian cancer patients the analysis showed a 5 fold significant reduction of the risk of death in patients with B genotype. However, postoperative residual tumor resulted the most important prognostic factor for overall survival. Conclusions: AB0 blood group might be a preoperative prognostic factor in epithelial ovarian cancer patients. According to the literature, postoperative residual disease remain the most important prognostic factor also in our study.",
keywords = "AB0 blood group, Neoadjuvant therapy, Ovarian cancer, Prognostic factor, Residual disease, Survival",
author = "Mandato, {Vincenzo Dario} and Federica Torricelli and Valentina Mastrofilippo and Gino Ciarlini and Debora Pirillo and Gianluca Annunziata and Bruno Casali and Martino Abrate and {La Sala}, {Giovanni Battista} and Lorenzo Aguzzoli",
year = "2019",
month = "1",
day = "1",
doi = "10.7150/jca.29272",
language = "English",
volume = "10",
pages = "1949--1957",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "9",

}

TY - JOUR

T1 - AB0 blood group and ovarian cancer survival

AU - Mandato, Vincenzo Dario

AU - Torricelli, Federica

AU - Mastrofilippo, Valentina

AU - Ciarlini, Gino

AU - Pirillo, Debora

AU - Annunziata, Gianluca

AU - Casali, Bruno

AU - Abrate, Martino

AU - La Sala, Giovanni Battista

AU - Aguzzoli, Lorenzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Epithelial ovarian cancer is the most lethal gynecological malignancy because is usually diagnosed at advanced stage. New prognostic factors have been investigated but these biomarkers do not have a strong direct relationship with survival. Several studies investigated the association between AB0 blood group with ovarian cancer but with conflicting results. We investigated the association between AB0 blood group and epithelial ovarian cancer patients consecutively surgically treated at our department from 2004 to 2015. Methods: Clinical charts of ovarian cancer patients treated and followed from 2004 to 2015 were checked for inclusion and exclusion criteria. Clinical and pathological data were recorded in an electronic separate, anonymous, password-protected database. All relevant data were extrapolated and used for final analysis. Results: A population of 265 ovarian cancer patients was analyzed in this study. 121 (45.6%) patients presented blood type 0, 112 (42.3%) had blood type A, 23 (8.7%) B and 9 (3.4%) AB. A significantly lower percentage of death (8.7%) in patients with blood type B in comparison with patients presenting different genotypes (group 0: 34.7%, group A: 32.1%, group AB: 22.2%) was found. In invasive serous ovarian cancer patients the analysis showed a 5 fold significant reduction of the risk of death in patients with B genotype. However, postoperative residual tumor resulted the most important prognostic factor for overall survival. Conclusions: AB0 blood group might be a preoperative prognostic factor in epithelial ovarian cancer patients. According to the literature, postoperative residual disease remain the most important prognostic factor also in our study.

AB - Background: Epithelial ovarian cancer is the most lethal gynecological malignancy because is usually diagnosed at advanced stage. New prognostic factors have been investigated but these biomarkers do not have a strong direct relationship with survival. Several studies investigated the association between AB0 blood group with ovarian cancer but with conflicting results. We investigated the association between AB0 blood group and epithelial ovarian cancer patients consecutively surgically treated at our department from 2004 to 2015. Methods: Clinical charts of ovarian cancer patients treated and followed from 2004 to 2015 were checked for inclusion and exclusion criteria. Clinical and pathological data were recorded in an electronic separate, anonymous, password-protected database. All relevant data were extrapolated and used for final analysis. Results: A population of 265 ovarian cancer patients was analyzed in this study. 121 (45.6%) patients presented blood type 0, 112 (42.3%) had blood type A, 23 (8.7%) B and 9 (3.4%) AB. A significantly lower percentage of death (8.7%) in patients with blood type B in comparison with patients presenting different genotypes (group 0: 34.7%, group A: 32.1%, group AB: 22.2%) was found. In invasive serous ovarian cancer patients the analysis showed a 5 fold significant reduction of the risk of death in patients with B genotype. However, postoperative residual tumor resulted the most important prognostic factor for overall survival. Conclusions: AB0 blood group might be a preoperative prognostic factor in epithelial ovarian cancer patients. According to the literature, postoperative residual disease remain the most important prognostic factor also in our study.

KW - AB0 blood group

KW - Neoadjuvant therapy

KW - Ovarian cancer

KW - Prognostic factor

KW - Residual disease

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85067306149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067306149&partnerID=8YFLogxK

U2 - 10.7150/jca.29272

DO - 10.7150/jca.29272

M3 - Article

AN - SCOPUS:85067306149

VL - 10

SP - 1949

EP - 1957

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 9

ER -